Paul Johnson wrote: >On Thursday 24 August 2006 14:29, Katipo wrote: > > >>You're in the States, and therefore classified as American market source. >>I'm in Australia, and it's all China and Korea here. >>Very little from South America or EU. >> >> > >I used to get a *lot* from Korea, almost all of it from Kornet. > That's the one!
> I have to >wonder if they cleaned up their act or went under: I haven't heard peep one >from Korea for months now. > > No, they're the biggest in Korea. > > >>Corporates employ off-shore spammers because they have the cheap labour >>resources ( a lot of the ISPs clients get free online in return for >>spamming), act as an identity buffer for public image factors, and being >>off-shore, the ISP, and therefore corporate identity, enjoys a level of >>insulation from prosecution. >> >> > >I haven't seen any corporate marketing of any kind via email, except from >ThinkGeek and Dotster, but I subscribed to their newsletters. At least in >the States, corporate spam is such a massively bad PR move that about the >only thing you're likely to get unsolicited via email with a corporate logo >on it is a phishing attempt from the EU or central Africa. > > > >>Last fiscal year, the American pharmaceutical sector invested $4 billion >>in direct advertising. >>Not all of that went to spammers, but if it did, it would have >>translated into an effective $20 billion in advertising value. >> >> > >I'm not sure any of it went to spammers, as the pharm companies themselves >lose money because of spammers selling knockoffs. > > But in many cases, they're not knock-offs. They're simply 'Black and Gold', or 'Home Brand' wrappings of the same product, while corporates disguise the act with screams of 'Patent theft'. Pharmaceutical companies have now moved into the 'off-shore' potential in a big way, by out-sourcing their latter day lab testing into the poorer areas of India, paying the beggar classes $100.00/progamme to act as guinea pigs. It accelerates the test programme with proven human application, is probably as economical as commercially bred lab rats, and India provides the suitably qualified, medical personnel to conduct the trials. Regards, -- To UNSUBSCRIBE, email to [EMAIL PROTECTED] with a subject of "unsubscribe". Trouble? Contact [EMAIL PROTECTED]
